EE9900549A - Uus sool - Google Patents

Uus sool

Info

Publication number
EE9900549A
EE9900549A EEP199900549A EEP9900549A EE9900549A EE 9900549 A EE9900549 A EE 9900549A EE P199900549 A EEP199900549 A EE P199900549A EE P9900549 A EEP9900549 A EE P9900549A EE 9900549 A EE9900549 A EE 9900549A
Authority
EE
Estonia
Prior art keywords
new salt
salt
new
Prior art date
Application number
EEP199900549A
Other languages
English (en)
Inventor
Nyqvist H�kan
D. Sohn Daniel
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9900549A publication Critical patent/EE9900549A/et
Publication of EE03874B1 publication Critical patent/EE03874B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
EEP199900549A 1997-05-30 1998-05-15 (R)-3-N,N-ditsüklobutüülamino-8-fluoro-3,4-dihüdro-2H-1-bensopüraan-5-karboksam iidvesinik- tartraat, selle valmistamise meetod ja seda sisaldav ravimkoostis EE03874B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt
PCT/SE1998/000907 WO1998054166A1 (en) 1997-05-30 1998-05-15 A new salt

Publications (2)

Publication Number Publication Date
EE9900549A true EE9900549A (et) 2000-06-15
EE03874B1 EE03874B1 (et) 2002-10-15

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900549A EE03874B1 (et) 1997-05-30 1998-05-15 (R)-3-N,N-ditsüklobutüülamino-8-fluoro-3,4-dihüdro-2H-1-bensopüraan-5-karboksam iidvesinik- tartraat, selle valmistamise meetod ja seda sisaldav ravimkoostis

Country Status (33)

Country Link
US (2) US6858645B2 (et)
EP (1) EP0984952B1 (et)
JP (1) JP3554338B2 (et)
KR (1) KR20010013127A (et)
CN (1) CN1198814C (et)
AR (1) AR012751A1 (et)
AT (1) ATE228121T1 (et)
AU (1) AU729301B2 (et)
BG (1) BG64051B1 (et)
BR (1) BR9809519A (et)
CA (1) CA2291732C (et)
DE (1) DE69809547T2 (et)
DK (1) DK0984952T3 (et)
EE (1) EE03874B1 (et)
ES (1) ES2187030T3 (et)
HU (1) HUP0001878A3 (et)
ID (1) ID23794A (et)
IL (1) IL133234A (et)
IS (1) IS1943B (et)
MY (1) MY117960A (et)
NO (1) NO995853L (et)
NZ (1) NZ501075A (et)
PL (1) PL337181A1 (et)
PT (1) PT984952E (et)
RU (1) RU2193560C2 (et)
SE (1) SE510305C2 (et)
SK (1) SK282755B6 (et)
TR (1) TR199902926T2 (et)
TW (1) TW510899B (et)
UA (1) UA53720C2 (et)
WO (1) WO1998054166A1 (et)
YU (1) YU62499A (et)
ZA (1) ZA984486B (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
RU2340333C2 (ru) * 2002-08-15 2008-12-10 Вайет Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
EP2022110B1 (en) * 2006-05-11 2011-10-12 Johnson Controls Saft Advanced Power Solutions LLC Modular battery system
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN103788043B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
WO2014174102A1 (en) * 2013-04-26 2014-10-30 Sanofi Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(s)-2-[methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl piperazin-1 -yl)-3-oxo-propryl]amide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63474B1 (en) * 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
US5616610A (en) 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
RU2047614C1 (ru) * 1992-06-15 1995-11-10 Джон Вайс энд Бразер Лимитед Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
US5990114A (en) 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria

Also Published As

Publication number Publication date
IS5270A (is) 1999-11-24
PT984952E (pt) 2003-03-31
MY117960A (en) 2004-08-30
DK0984952T3 (da) 2003-02-24
ES2187030T3 (es) 2003-05-16
NO995853D0 (no) 1999-11-29
TW510899B (en) 2002-11-21
CN1258290A (zh) 2000-06-28
SK282755B6 (sk) 2002-12-03
ZA984486B (en) 1998-11-30
UA53720C2 (uk) 2003-02-17
EP0984952A1 (en) 2000-03-15
IL133234A0 (en) 2001-03-19
AU7792398A (en) 1998-12-30
JP2002501527A (ja) 2002-01-15
SE9702066L (sv) 1998-12-01
IL133234A (en) 2004-05-12
SE510305C2 (sv) 1999-05-10
EE03874B1 (et) 2002-10-15
HK1025575A1 (en) 2000-11-17
NZ501075A (en) 2001-08-31
KR20010013127A (ko) 2001-02-26
PL337181A1 (en) 2000-08-14
ID23794A (id) 2000-05-11
TR199902926T2 (xx) 2000-03-21
DE69809547T2 (de) 2003-08-21
RU2193560C2 (ru) 2002-11-27
DE69809547D1 (de) 2003-01-02
CA2291732A1 (en) 1998-12-03
AU729301B2 (en) 2001-02-01
BG103949A (en) 2000-07-31
ATE228121T1 (de) 2002-12-15
US20030109576A1 (en) 2003-06-12
US20050085532A1 (en) 2005-04-21
SK159499A3 (en) 2000-10-09
SE9702066D0 (sv) 1997-05-30
US6858645B2 (en) 2005-02-22
IS1943B (is) 2004-08-13
HUP0001878A3 (en) 2002-04-29
BG64051B1 (bg) 2003-11-28
YU62499A (sh) 2002-06-19
WO1998054166A1 (en) 1998-12-03
CA2291732C (en) 2003-12-30
JP3554338B2 (ja) 2004-08-18
CN1198814C (zh) 2005-04-27
HUP0001878A2 (hu) 2001-05-28
NO995853L (no) 2000-01-31
AR012751A1 (es) 2000-11-08
BR9809519A (pt) 2000-06-20
EP0984952B1 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
EE200000192A (et) Uus kombinatsioon
EE200000640A (et) Uus kasutamine
DK0860428T3 (da) Sulphonamidderivater
DE69829430D1 (de) Okklusionsvorrichtung
IS5354A (is) Ný efnasambönd
NO20010694D0 (no) Cornealt pålegg
EE9900593A (et) Omeprasooli naatriumisool
NL1009421A1 (nl) Applicator.
EE200000022A (et) Uus ravimvorm
PT1036083E (pt) Novos 9a-azalidos
EA200000208A1 (ru) Иммуномодулятор с антимикробной и антимикобактериальной активностью, способ его получения и лекарственный препарат для лечения микобактериозов, хронических неспецифических заболеваний легких, заболеваний, передающихся половым путем, и иммунодефицита на их основе
NO995147D0 (no) Kontrastmidler
DK0984952T3 (da) Hidtil ukendt salt
DK0983266T3 (da) Hidtil ukendte tetrahydrosioquinolinthiophencarboximidamider
EE9900455A (et) Uus menetlus
NL1007832A1 (nl) Houder.
SE9703483D0 (sv) New use
AR008310A1 (es) Metodos nuevos
ID19473A (id) 24-homo-26,27-heksafluoro-kolkalsiferol
FI971438A0 (fi) Koppling laemplig foer spaennings- eller spaenningsfri arbete, saerskilt koppling foer ljusbaogs- eller oeverstoemsskydd
FI971391A0 (fi) Koppling laemplig foer spaenningsarbete, saerskilt koppling foer ljusbaogs- eller oeverstoemsskydd
NO974138D0 (no) Kontrastmidler
FI3112U1 (fi) Maila, erityisesti pesäpallomaila
TR199802513A3 (tr) N-(4- Karbamimido- fenil)- fenilglisinamid türevleri.
SE9801370D0 (sv) New use

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20060515